Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Disability after minor stroke and TIA: A secondary analysis of the SOCRATES trial.

Cucchiara B, George DK, Kasner SE, Knutsson M, Denison H, Ladenvall P, Amarenco P, Johnston SC.

Neurology. 2019 Aug 13;93(7):e708-e716. doi: 10.1212/WNL.0000000000007936. Epub 2019 Jul 11.

PMID:
31296654
2.

Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.

Easton JD, Denison H, Evans SR, Knutsson M, Amarenco P, Albers GW, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KL, Johnston SC; SOCRATES Steering Committee and Investigators.

Int J Stroke. 2019 May 15:1747493019851282. doi: 10.1177/1747493019851282. [Epub ahead of print]

PMID:
31092152
3.

Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.

Molina CA, Johnston SC, Ladenvall P, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Knutsson M, Minematsu K, Röther J, Wang Y, Wong KSL; SOCRATES Steering Committee and Investigators.

Stroke. 2019 Mar;50(3):675-682. doi: 10.1161/STROKEAHA.118.022675. Erratum in: Stroke. 2019 Apr;50(4):e118.

PMID:
30776996
4.

The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design.

Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y; THALES Investigators.

Int J Stroke. 2019 Feb 12:1747493019830307. doi: 10.1177/1747493019830307. [Epub ahead of print]

PMID:
30747613
5.

Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial.

Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Himmelmann A, Kasner SE, Knutsson M, Ladenvall P, Minematsu K, Molina CA, Wang Y, Johnston SC; SOCRATES Steering Committee and Investigators.

Stroke. 2018 Jul;49(7):1678-1685. doi: 10.1161/STROKEAHA.118.020553. Epub 2018 Jun 18.

6.

Quality of life after percutaneous closure of patent foramen ovale in patients after cryptogenic stroke compared to a normative sample.

Mirzada N, Ladenvall P, Hansson PO, Eriksson P, Taft C, Dellborg M.

Int J Cardiol. 2018 Apr 15;257:46-49. doi: 10.1016/j.ijcard.2018.01.120. Epub 2018 Jan 31.

PMID:
29422265
7.

Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.

Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators.

Stroke. 2017 Sep;48(9):2480-2487. doi: 10.1161/STROKEAHA.117.017217. Epub 2017 Jul 18.

PMID:
28720658
8.

Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.

Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators.

Lancet Neurol. 2017 Apr;16(4):301-310. doi: 10.1016/S1474-4422(17)30038-8. Epub 2017 Feb 23.

PMID:
28238711
9.

Low aerobic capacity in middle-aged men associated with increased mortality rates during 45 years of follow-up.

Ladenvall P, Persson CU, Mandalenakis Z, Wilhelmsen L, Grimby G, Svärdsudd K, Hansson PO.

Eur J Prev Cardiol. 2016 Sep;23(14):1557-64. doi: 10.1177/2047487316655466. Epub 2016 Jul 26. Erratum in: Eur J Prev Cardiol. 2017 Mar;24(4):NP2.

PMID:
27462049
10.

Recurrent stroke in patients with patent foramen ovale: An observational prospective study of percutaneous closure of PFO versus non-closure.

Mirzada N, Ladenvall P, Hansson PO, Eriksson P, Dellborg M.

Int J Cardiol. 2015 Sep 15;195:293-9. doi: 10.1016/j.ijcard.2015.05.088. Epub 2015 May 21.

PMID:
26056962
11.

Genetic variation at the human connexin 43 locus but not at the connexin 40 locus is associated with left bundle branch block.

Ladenvall P, Andersson B, Dellborg M, Hansson PO, Eriksson H, Thelle D, Eriksson P.

Open Heart. 2015 Apr 10;2(1):e000187. doi: 10.1136/openhrt-2014-000187. eCollection 2015.

12.

Absence of significant aortic regurgitation seven years after closure of patent foramen ovale.

Mirzada N, Ladenvall P, Johansson MC.

Int J Cardiol Heart Vessel. 2014 Jul 27;4:59-62. doi: 10.1016/j.ijchv.2014.06.014. eCollection 2014 Sep.

13.

Seven-year follow-up of percutaneous closure of patent foramen ovale.

Mirzada N, Ladenvall P, Hansson PO, Johansson MC, Furenäs E, Eriksson P, Dellborg M.

Int J Cardiol Heart Vessel. 2013 Nov 14;1:32-36. doi: 10.1016/j.ijchv.2013.11.003. eCollection 2013 Dec.

14.

[Patent foramen ovale can cause cryptogenic stroke. Transcatheter closure as an alternative to medical therapy must be evaluated more].

Ladenvall P, Dellborg M.

Lakartidningen. 2013 Sep 4-10;110(36):1524-5. Swedish. No abstract available.

PMID:
24163903
15.

Multidisciplinary management of patent foramen ovale (PFO) and cryptogenic stroke/TIA.

Mirzada N, Ladenvall P, Hansson PO, Eriksson P, Dellborg M.

J Multidiscip Healthc. 2013 Sep 16;6:357-63. doi: 10.2147/JMDH.S46890. Review.

16.

Bayesian methods for meta-analysis of causal relationships estimated using genetic instrumental variables.

Burgess S, Thompson SG; CRP CHD Genetics Collaboration, Burgess S, Thompson SG, Andrews G, Samani NJ, Hall A, Whincup P, Morris R, Lawlor DA, Davey Smith G, Timpson N, Ebrahim S, Ben-Shlomo Y, Davey Smith G, Timpson N, Brown M, Ricketts S, Sandhu M, Reiner A, Psaty B, Lange L, Cushman M, Hung J, Thompson P, Beilby J, Warrington N, Palmer LJ, Nordestgaard BG, Tybjaerg-Hansen A, Zacho J, Wu C, Lowe G, Tzoulaki I, Kumari M, Sandhu M, Yamamoto JF, Chiodini B, Franzosi M, Hankey GJ, Jamrozik K, Palmer L, Rimm E, Pai J, Psaty B, Heckbert S, Bis J, Anand S, Engert J, Collins R, Clarke R, Melander O, Berglund G, Ladenvall P, Johansson L, Jansson JH, Hallmans G, Hingorani A, Humphries S, Rimm E, Manson J, Pai J, Watkins H, Clarke R, Hopewell J, Saleheen D, Frossard R, Danesh J, Sattar N, Robertson M, Shepherd J, Schaefer E, Hofman A, Witteman JC, Kardys I, Ben-Shlomo Y, Davey Smith G, Timpson N, de Faire U, Bennet A, Sattar N, Ford I, Packard C, Kumari M, Manson J, Lawlor DA, Davey Smith G, Anand S, Collins R, Casas JP, Danesh J, Davey Smith G, Franzosi M, Hingorani A, Lawlor DA, Manson J, Nordestgaard BG, Samani NJ, Sandhu M, Smeeth L, Wensley F, Anand S, Bowden J, Burgess S, Casas JP, Di Angelantonio E, Engert J, Gao P, Shah T, Smeeth L, Thompson SG, Verzilli C, Walker M, Whittaker J, Hingorani A, Danesh J.

Stat Med. 2010 May 30;29(12):1298-311. doi: 10.1002/sim.3843.

17.

C-reactive protein is a determinant of first-ever stroke: prospective nested case-referent study.

Andersson J, Johansson L, Ladenvall P, Wiklund PG, Stegmayr B, Jern C, Boman K.

Cerebrovasc Dis. 2009;27(6):544-51. doi: 10.1159/000214217. Epub 2009 Apr 24.

PMID:
19390179
18.

Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype.

Ladenvall C, Jood K, Blomstrand C, Nilsson S, Jern C, Ladenvall P.

Stroke. 2006 Aug;37(8):2018-23. Epub 2006 Jun 29.

PMID:
16809555
19.

Fibrinolytic gene polymorphism and ischemic stroke.

Jood K, Ladenvall P, Tjärnlund-Wolf A, Ladenvall C, Andersson M, Nilsson S, Blomstrand C, Jern C.

Stroke. 2005 Oct;36(10):2077-81. Epub 2005 Sep 22.

PMID:
16179568
20.

Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA.

Ladenvall P, Nilsson S, Jood K, Rosengren A, Blomstrand C, Jern C.

Eur J Hum Genet. 2003 Aug;11(8):603-10.

21.

Rapid genotyping of haemostatic gene polymorphisms using the 5' nuclease assay.

Tjärnlund A, Andersson M, Jood K, Ladenvall P, Jern C.

Thromb Haemost. 2003 May;89(5):936-42.

PMID:
12719792
22.

Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction.

Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, Tjärnlund A, Jern C, Boman K.

Thromb Haemost. 2002 Jan;87(1):105-9.

PMID:
11848437
23.

Eight single-nucleotide polymorphisms (SNPs) at the human tissue-type plasminogen activator (t-PA) locus.

Ladenvall P, Wall U, Jern S, Jern C.

J Hum Genet. 2001;46(12):737-8. No abstract available.

PMID:
11776389
25.

Gene polymorphism of t-PA is associated with forearm vascular release rate of t-PA.

Jern C, Ladenvall P, Wall U, Jern S.

Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):454-9.

PMID:
9974431

Supplemental Content

Loading ...
Support Center